Eli Lilly, Regeneron, and Fujifilm are among the seven companies selected for the FDA’s PreCheck Pilot Program, aimed at enhancing drug manufacturing and supply chain resilience in the United States. The initiative includes participation from Amneal, Cellares, Kriya, and Kyowa Kirin, reflecting a diverse group of stakeholders in the pharmaceutical landscape.
This program is a strategic response to the increasing vulnerabilities in the drug supply chain, which have been exacerbated by global disruptions and heightened regulatory scrutiny. By collaborating with these industry leaders, the FDA seeks to leverage their expertise and innovative practices to establish more robust manufacturing protocols and ensure consistent product availability.
The implications for pharmaceutical B2B professionals are significant, as this initiative could set new standards for quality assurance and regulatory compliance. Companies involved may gain insights that enhance their operational efficiencies and mitigate risks associated with supply chain disruptions, ultimately benefiting the broader industry.
Get started today with Solo access →
